Results 131 to 140 of about 3,237,599 (246)

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Fractional-order lead networks to avoid limit cycle in control loops with dead zone and plant servo system

open access: yesNonlinear Engineering
The fractional-order controllers (FOCs) have recently had a significant impact on control applications. However, they still need further research for feedback systems with hard nonlinearities, such as dead zones.
Maione Guido
doaj   +1 more source

On the existence and the number of limit cycles in evolutionary games [PDF]

open access: yes
In this paper it is shown that an extended evolutionary system proposed by Hofbauer and Sigmund (1998) may be transformed into a Kukles system. Then a Dulac-Cherkas function related to the Kukles system is derived, which allows us to determine the number
Araujo, Ricardo Azevedo   +1 more
core  

Limit cycle analysis using a system right inverse

open access: yes, 2005
The variational system obtained by linearizing a dynamical system along a limit cycle is always non-invertible. This follows because the limit cycle is only unique modulo time translation.
Jönsson, Ulf,, Megretski, A.
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

APROKSIMASI LIMIT CYCLE PADA PERSAMAAN VAN DER POL DAN DUFFING TERIKAT

open access: yes, 2015
Pada skripsi ini dikaji aproksimasi limit cycle pada persamaan van der Pol dan Du ng terikat. Limit cycle adalah lintasan tutup pada bidang fasa suatu persamaan diferensial nonlinier.
RATI, FEBRIANTI
core   +2 more sources

A General Approach for Construction the Limit Cycle Loci of Multiple-Nonlinearity Systems

open access: yes, 2012
[[abstract]]The authors present a widely convergent algorithm for finding a limit cycle of systems with multiple nonlinearities. A systematic approach is proposed for constructing the limit cycle loci on the parameter planes.
H. C. Chang;Ching-Tsai Pan;C. C. Wei;C.L. Huang
core   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy